Pfizer CEO Albert Bourla (Drew Angerer/Getty Images)

Pfiz­er's trou­ble-prone McPher­son plant — now ramp­ing up vac­cine sup­plies — was cit­ed for con­tin­u­ing vi­o­la­tions in ear­ly 2020

A few days ago, as Pfiz­er CEO Al­bert Bourla com­mit­ted to ramp­ing up pro­duc­tion of its Covid-19 vac­cine, the phar­ma gi­ant point­ed to plans to add its man­u­fac­tur­ing plant in McPher­son, KS to the group of fa­cil­i­ties churn­ing out their mR­NA vac­cine de­vel­oped by BioN­Tech.

But a quick check of Google would show any­one that the plant, ob­tained from Hos­pi­ra in the 2015 buy­out, has reg­u­lar­ly been in hot wa­ter with the FDA over vi­o­la­tions of fed­er­al reg­u­la­to­ry stan­dards. Most sig­nif­i­cant­ly, Pfiz­er earned a harsh warn­ing let­ter from the FDA in 2017 that made it clear the FDA wasn’t hap­py with the re­me­di­a­tion ef­forts be­ing made at the plant in the 2 years since the ac­qui­si­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.